Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;79(9):1147-1157.
doi: 10.1007/s00228-023-03523-2. Epub 2023 Jun 28.

Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management

Dimy Fluyau  1 , Vasanth Kattalai Kailasam  2 , Christopher G Pierre  3
Affiliations
Review

Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management

Dimy Fluyau et al. Eur J Clin Pharmacol. 2023 Sep.

Abstract

Purpose: To compare the efficacy and safety of non-benzodiazepines (non-BZDs) to benzodiazepines (BZDs) in the treatment of alcohol withdrawal syndrome (AWS).

Methods: For relevant literature, Google Scholar, PubMed, Embase, OVID MEDLINE, EBSCO, Cochrane Central Registry of Controlled Trials, Web of Science, and Scopus were searched. Randomized control trials (RCTs) were included, omitted were nonblinded trials, blinded trials that were not randomized, and open-label studies. The Effective Public Health Practice Project Quality Assessment was used to assess the trial's quality. A meta-analysis and a narrative synthesis were carried out.

Results: Twenty non-BZDs and five BZDs were investigated in thirty RCTs. Meta-analysis favored gabapentin over chlordiazepoxide and lorazepam (d = 0.563, p < 0.001) and carbamazepine over oxazepam and lorazepam (d = 0.376, p = 0.029), for reducing Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scale scores. Eleven non-BZDs fared better than BZDs for reducing CIWA-Ar, Total Severity Assessment, Selective Severity Assessment, Borg and Weinholdt, and Gross Rating Scale for Alcohol Withdrawal scores. Eight non-BZDs outmatched BZDs regarding autonomic, motor, awareness, and psychiatric symptoms. Sedation and fatigue were prevalent in BZDs, while seizures were prevalent in non-BZDs.

Conclusion: For AWS treatments, non-BZDs are superior to or equally effective as BZDs. Non-BZD adverse events warrant further investigation. Agents that inhibit gated ion channels are promising candidates.

Protocol registration: PROSPERO CRD42022384875.

Keywords: Alcohol withdrawal; Benzodiazepines; Efficacy; Meta-analysis; Non-benzodiazepines; Safety; Systematic review.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Saitz R (1998) Introduction to alcohol withdrawal. Alcohol Health Res World 22(1):5–12 - PubMed - PMC
    1. Trevisan LA, Boutros N, Petrakis IL, Krystal JH (1998) Complications of alcohol withdrawal: pathophysiological insights. Alcohol Health Res World 22(1):61–66 - PubMed - PMC
    1. McKeon A, Frye MA, Delanty N (2008) Alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 79(8):854–862. https://doi.org/10.1136/jnnp.2007.128322 - DOI - PubMed
    1. Campos J, Roca L, Gude F, Gonzalez-Quintela A (2011) Long-term mortality of patients admitted to the hospital with alcohol withdrawal syndrome. Alcohol Clin Exp Res 35(6):1180–1186. https://doi.org/10.1111/j.1530-0277.2011.01451.x - DOI - PubMed
    1. Becker HC (2008) Alcohol dependence, withdrawal, and relapse. Alcohol Res Health 31(4):348–361 - PubMed - PMC

MeSH terms

LinkOut - more resources